Singapore Cancer Diagnostics Startup Gets $77 Million in Funding
- Series C fundraising round values MiRXES at $500 million
- MiRXES eyes IPO or private funds in 18 months to fuel growth
This article is for subscribers only.
Singaporean biotechnology startup MiRXES Pte raised $77 million from investors led by CR-CP Life Science Fund to deliver early detection tests for cancer and other diseases.
Other backers in the Series C funding round include Rock Springs Capital, EDBI, CCB International Holdings Ltd. and Keytone Ventures, the company said in a statement. The round, which brings the total amount of money raised to date to $120 million, values the seven-year-old startup at $500 million, according to a person with knowledge of the matter who asked not to be identified.